Director/PDMR Shareholding (5416Z)

TIDMHIK

RNS Number : 5416Z

Hikma Pharmaceuticals Plc

16 March 2012

Hikma Pharmaceuticals PLC - LTIP Awards

LONDON, 16 March 2012: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces that the Remuneration Committee has made the following nil-cost awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the LTIP were made on 16 March 2012 at a price of GBP7.40p per ordinary share as follows:-

 
 Name of PDMR               Number of LTIP Shares 
 Bassam Kanaan                             46,300 
 Michael Raya                              43,800 
 Khalid Nabilsi                            26,000 
 Riad Mishlawi                             20,700 
 Henry Knowles                             23,700 
 Susan Ringdal                             22,200 
 Jason Grenfell-Gardener                   20,900

The shares subject to the LTIP awards will only be released to the participants in three years time, subject to their continued employment and the satisfaction of the comparative Total Shareholder Return ("TSR"), sales growth, earnings per share ("EPS") growth and return on invested capital ("ROIC") performance targets. Half of the award is subject to TSR against the Comparator Group and requires at least upper quartile performance to vest in full. The remaining half is split equally between the financial targets and requires sales growth of 13%, EPS growth of 20% and ROIC of 12% to vest in full. Each target is measured individually and is independent of the other targets.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

   Henry Knowles                                                +44 20 7399 2760

Company Secretary

   Susan Ringdal                                                 +44 20 7399 2770

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non--branded generic and in--licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBUGDXGDBBGDL

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024